ResearcherHarvard UniversityActive in the last 2 years
George Molina
Matched on ORCID iD 0000-0001-6516-2121; OpenAlex author ID A5067851720. Sources: OpenAlex.
Their work
- Papers
- 12 (first author 1, last author 6)
- Trials
- 0
- Grants
- 0
- Labs led
- 1
- Collaborators
- 37
2020: 1 paper · 2021: 1 paper · 2022: 1 paper · 2023: none · 2024: 1 paper · 2025: 1 paper · 2026: 7 papers
Papers 12
- Multimodal Neoadjuvant Therapy for Pancreatic Ductal Adenocarcinoma (PDAC) With Vascular Involvement: What Is the Impact of Radiation on Perioperative Outcomes… Co-author DOI 10.1002/jso.70387↗
- Impact of Institutional Radiotherapy Patient Volume on Postoperative and Oncologic Outcomes After Neoadjuvant Radiation for Pancreatic Cancer. Last author DOI 10.1002/jso.70401↗
- Geospatial variation in the treatment of medicare beneficiary pancreatic cancer patients: A SEER-Medicare cohort study. Last author DOI 10.1016/j.amjsurg.2025.116684↗
- Dendritic cell redundancy enables priming of anti-tumor CD4+ T cells in pancreatic cancer. Co-author DOI 10.1016/j.ccell.2026.04.005↗
- CD4 T cells convert transient responses to KRAS inhibition to durable remissions in pancreatic cancer. Co-author DOI 10.1016/j.cell.2026.08.045↗
- Adjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma after pathologic complete response to neoadjuvant treatment: necessary or overtreatment? Last author DOI 10.1016/j.gassur.2026.102542↗
- Utilization of Imaging in the Diagnosis and Surveillance of Pancreatic Ductal Adenocarcinoma (PDAC): Analysis of the TRICARE Data. Last author DOI 10.7759/cureus.110968↗
- Assessing Equity in Quality Care for Metastatic Pancreatic Cancer. Co-author DOI 10.6004/jnccn.2025.7043↗
- Impact of Tumor Response After Neoadjuvant Treatment on Overall Survival Among Patients With Pancreatic Ductal Adenocarcinoma: National Cancer Database Analysi… Last author DOI 10.7759/cureus.73524↗
- Advances and Remaining Challenges in the Treatment for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma. Last author DOI 10.3390/jcm11164866↗
- Racial Disparity in Pancreatoduodenectomy for Borderline Resectable Pancreatic Adenocarcinoma. Co-author DOI 10.1245/s10434-020-08717-x↗
- Neoadjuvant Therapy is Associated with Improved Survival in Borderline-Resectable Pancreatic Cancer. First author DOI 10.1245/s10434-019-08087-z↗
Closest collaborators
The 25 strongest of 37 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Thomas E. Clancy · 5 shared papers, 2020–2026 · strength 0.89
- Paper Impact of Tumor Response After Neoadjuvant Treatment on Overall Survival Among Patients With Pancreatic Ductal Adenocar… DOI 10.7759/cureus.73524↗
- Paper Dendritic cell redundancy enables priming of anti-tumor CD4+ T cells in pancreatic cancer. DOI 10.1016/j.ccell.2026.04.005↗
- Paper CD4 T cells convert transient responses to KRAS inhibition to durable remissions in pancreatic cancer. DOI 10.1016/j.cell.2026.08.045↗
- Jason S. Gold · 2 shared papers, 2024–2025 · strength 0.75
- Akhil Chawla · 3 shared papers, 2020–2026 · strength 0.70
- Paper Impact of Institutional Radiotherapy Patient Volume on Postoperative and Oncologic Outcomes After Neoadjuvant Radiation… DOI 10.1002/jso.70401↗
- Paper Multimodal Neoadjuvant Therapy for Pancreatic Ductal Adenocarcinoma (PDAC) With Vascular Involvement: What Is the Impac… DOI 10.1002/jso.70387↗
- Paper Neoadjuvant Therapy is Associated with Improved Survival in Borderline-Resectable Pancreatic Cancer. DOI 10.1245/s10434-019-08087-z↗
- Yun Jee Kang · 1 shared paper, 2026 · strength 0.50
- Brian Matthew Wolpin · 3 shared papers, 2020–2026 · strength 0.50
- Paper Dendritic cell redundancy enables priming of anti-tumor CD4+ T cells in pancreatic cancer. DOI 10.1016/j.ccell.2026.04.005↗
- Paper CD4 T cells convert transient responses to KRAS inhibition to durable remissions in pancreatic cancer. DOI 10.1016/j.cell.2026.08.045↗
- Paper Neoadjuvant Therapy is Associated with Improved Survival in Borderline-Resectable Pancreatic Cancer. DOI 10.1245/s10434-019-08087-z↗
- Joseph Douglas Mancias · 3 shared papers, 2020–2026 · strength 0.50
- Paper Dendritic cell redundancy enables priming of anti-tumor CD4+ T cells in pancreatic cancer. DOI 10.1016/j.ccell.2026.04.005↗
- Paper CD4 T cells convert transient responses to KRAS inhibition to durable remissions in pancreatic cancer. DOI 10.1016/j.cell.2026.08.045↗
- Paper Neoadjuvant Therapy is Associated with Improved Survival in Borderline-Resectable Pancreatic Cancer. DOI 10.1245/s10434-019-08087-z↗
- Stanley W. Ashley · 2 shared papers, 2022–2024 · strength 0.48
- Paper Advances and Remaining Challenges in the Treatment for Borderline Resectable and Locally Advanced Pancreatic Ductal Ade… DOI 10.3390/jcm11164866↗
- Paper Impact of Tumor Response After Neoadjuvant Treatment on Overall Survival Among Patients With Pancreatic Ductal Adenocar… DOI 10.7759/cureus.73524↗
- Megan L. Sulciner · 2 shared papers, 2022–2024 · strength 0.48
- Paper Advances and Remaining Challenges in the Treatment for Borderline Resectable and Locally Advanced Pancreatic Ductal Ade… DOI 10.3390/jcm11164866↗
- Paper Impact of Tumor Response After Neoadjuvant Treatment on Overall Survival Among Patients With Pancreatic Ductal Adenocar… DOI 10.7759/cureus.73524↗
- Maite Liem · 1 shared paper, 2026 · strength 0.43
- Harshabad Singh · 2 shared papers, 2026 · strength 0.38
- Michael Lawrence Dougan · 2 shared papers, 2026 · strength 0.38
- Courtney T.S. Kureshi · 2 shared papers, 2026 · strength 0.38
- Chong Zuo · 2 shared papers, 2026 · strength 0.38
- Douglas Adam Rubinson · 2 shared papers, 2026 · strength 0.38
- Brandon M. Huffman · 2 shared papers, 2026 · strength 0.38
- Jonathan Andrew Nowak · 2 shared papers, 2026 · strength 0.38
- Kimberly J. Perez · 2 shared papers, 2026 · strength 0.38
- Stephanie K. Dougan · 2 shared papers, 2026 · strength 0.38
- James M. Cleary · 2 shared papers, 2026 · strength 0.38
- Abolfazl Salari · 1 shared paper, 2026 · strength 0.36
- Anne Pannekoek · 1 shared paper, 2026 · strength 0.33
- Jiping Wang · 2 shared papers, 2020–2021 · strength 0.29
- Judy Caroline Boughey · 1 shared paper, 2026 · strength 0.25
- Dhruv J. Patel · 1 shared paper, 2026 · strength 0.25
- David J. Bentrem · 1 shared paper, 2026 · strength 0.25
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.